Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piper

Showing results (411-420 of 455) with videos related to

Pageof 46
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2018
Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed DosingJessica E Justman, Gonasagrie Lulu Nair, Craig W Hendrix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2016
Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical TenofovirLisa M Noguchi, Elizabeth T Montgomery, Joseph R Biggio, et al.
The Journal of Infectious Diseases|April 24, 2024
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV PreventionSharon A Riddler, Clifton W Kelly, Craig J Hoesley, et al.
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Cell Reports. Medicine|June 4, 2026
Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2Guillem Montamat-Garcia, Joseph C F Ng, Alexander T Stewart, et al.
The Lancet. HIV|February 13, 2026
Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trialFelix G Mhlanga, Daniel W Szydlo, Ashley J Mayo, et al.
The Lancet. HIV|February 15, 2025
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trialLisa M Noguchi, Maxensia Owor, Nyaradzo M Mgodi, et al.
Frontiers in Immunology|July 11, 2018
CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-αChristopher J M Piper, Meredyth G Ll Wilkinson, Claire T Deakin, et al.
Pageof 46

Showing results (411-420 of 455) with videos related to

Sort By:
Pageof 46
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2018
Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed DosingJessica E Justman, Gonasagrie Lulu Nair, Craig W Hendrix, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2019
Brief Report: Routine Use of Oral PrEP in a Phase 2 Rectal Microbicide Study of Tenofovir Reduced-Glycerin 1% Gel (MTN-017)Albert Y Liu, Aliza Norwood, Holly Gundacker, et al.
Plos One|June 5, 2024
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal ringsSharon L Achilles, Clifton W Kelly, Craig J Hoesley, et al.
Antimicrobial Agents and Chemotherapy|July 13, 2016
Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical TenofovirLisa M Noguchi, Elizabeth T Montgomery, Joseph R Biggio, et al.
The Journal of Infectious Diseases|April 24, 2024
A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV PreventionSharon A Riddler, Clifton W Kelly, Craig J Hoesley, et al.
Journal of the International AIDS Society|June 12, 2021
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United StatesAlbert Y Liu, Clara Dominguez Islas, Holly Gundacker, et al.
Cell Reports. Medicine|June 4, 2026
Human primary antibody response to vaccination follows a partially sequential class-switching program with a checkpoint at IGHG2Guillem Montamat-Garcia, Joseph C F Ng, Alexander T Stewart, et al.
The Lancet. HIV|February 13, 2026
Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trialFelix G Mhlanga, Daniel W Szydlo, Ashley J Mayo, et al.
The Lancet. HIV|February 15, 2025
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trialLisa M Noguchi, Maxensia Owor, Nyaradzo M Mgodi, et al.
Frontiers in Immunology|July 11, 2018
CD19<sup>+</sup>CD24<sup>hi</sup>CD38<sup>hi</sup> B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-αChristopher J M Piper, Meredyth G Ll Wilkinson, Claire T Deakin, et al.
Pageof 46